Strategic PICO Planning in Oncology Markets
In today’s dynamic healthcare environment, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is critical to successful evidence generation. With evolving regulatory frameworks—like the European Joint Clinical Assessment (JCA)—now leveraging PICOs to guide therapy evaluations, NAVLIN by EVERSANA® enables clients to anticipate HTA requirements, align internal stakeholders, and make confident, evidence-driven decisions across the asset lifecycle.
In a saturated oncology market, NAVLIN by EVERSANA equipped a leading biopharmaceutical company with precision PICO strategies to meet HTA expectations and optimize evidence planning.
Results Delivered
- Strategic, country-specific PICOs across key patient segments
- Built-in triggers for adapting to market and regulatory shifts
- Analogue-based insights to guide internal planning and payer alignment
What You’ll Discover
Gain insights into how NAVLIN by EVERSANA helped decode complex oncology access challenges, including:
- Treatment pathway perspectives from HTA, regulatory, and clinical trial angles
- Strategic use of real-world evidence and indirect treatment comparisons
- The impact of patient-reported outcomes on reimbursement decisions
- Lessons from trial design, HTA restrictions, and evolving EU JCA dynamics
Download the case study to uncover the strategies behind the success.
Author
As a Director of Global Market Access and Pricing, Richard leads global consulting engagements within EVERSANA. Richard comes with 13+ year of Life Sciences Consulting and Industry experience. He supported 40+ pharma brands preparing…
Shivani Shah is Senior Consultant at EVERSANA and has around 6 years of experience working as consultant in pharmaceutical and life-science industry. Prior to joining EVERSANA, she has worked at one of the top…